167 related articles for article (PubMed ID: 28144152)
1. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study.
Beisland C; Johannesen TB; Klepp O; Axcrona U; Torgersen KM; Kowalski J; Solli O; Sandin R; Oldenburg J
Onco Targets Ther; 2017; 10():371-385. PubMed ID: 28144152
[TBL] [Abstract][Full Text] [Related]
2. Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations.
Lindskog M; Wahlgren T; Sandin R; Kowalski J; Jakobsson M; Lundstam S; Ljungberg B; Harmenberg U
Urol Oncol; 2017 Sep; 35(9):541.e15-541.e22. PubMed ID: 28623071
[TBL] [Abstract][Full Text] [Related]
3. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of sarcomatoid features in metastatic renal cell carcinoma treated with cytoreductive nephrectomy and targeted therapy.
Cortese BD; Chelluri R; Xia L; Ostrowski DA; Roberson DS; Strother M; Ding JM; Schwartz L; Lee DJ; Guzzo TJ
Am J Clin Exp Urol; 2022; 10(5):327-333. PubMed ID: 36313210
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
6. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract][Full Text] [Related]
7. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry.
Tsimafeyeu I; Zolotareva T; Varlamov S; Zukov R; Petkau V; Mazhbich M; Statsenko G; Safina S; Zaitsev I; Sakaeva D; Popov A; Borisov P; Vladimirova L
Clin Genitourin Cancer; 2017 Dec; 15(6):e1069-e1072. PubMed ID: 28882737
[TBL] [Abstract][Full Text] [Related]
8. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
Pal SK; Nelson RA; Vogelzang N
PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
[TBL] [Abstract][Full Text] [Related]
9. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
10. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry.
Tsimafeyeu I; Shatkovskaya O; Krasny S; Nurgaliev N; Varlamov I; Petkau V; Safina S; Zukov R; Mazhbich M; Statsenko G; Varlamov S; Novikova O; Zaitsev I; Moiseyev P; Rolevich A; Evmenenko A; Popova I; Kaidarova D; Vladimirova L
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1331. PubMed ID: 33369240
[TBL] [Abstract][Full Text] [Related]
11. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
Bakouny Z; El Zarif T; Dudani S; Connor Wells J; Gan CL; Donskov F; Shapiro J; Davis ID; Parnis F; Ravi P; Steinharter JA; Agarwal N; Alva A; Wood L; Kapoor A; Ruiz Morales JM; Kollmannsberger C; Beuselinck B; Xie W; Heng DYC; Choueiri TK
Eur Urol; 2023 Feb; 83(2):145-151. PubMed ID: 36272943
[TBL] [Abstract][Full Text] [Related]
12. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
Gross EE; Li M; Yin M; Orcutt D; Hussey D; Trott E; Holt SK; Dwyer ER; Kramer J; Oliva K; Gore JL; Schade GR; Lin DW; Tykodi SS; Hall ET; Thompson JA; Parikh A; Yang Y; Collier KA; Miah A; Mori-Vogt S; Hinkley M; Mortazavi A; Monk P; Folefac E; Clinton SK; Psutka SP
Urol Oncol; 2023 Jan; 41(1):51.e25-51.e31. PubMed ID: 36441070
[TBL] [Abstract][Full Text] [Related]
13. Glutathione peroxidase family and survival prognosis in patients with renal cell carcinoma.
Li J; Huo S; Zhang R; Shi C; Sun N; Liu Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 May; 47(5):562-572. PubMed ID: 35753726
[TBL] [Abstract][Full Text] [Related]
14. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
Staehler M; Goebell PJ; Müller L; Emde TO; Wetzel N; Kruggel L; Jänicke M; Marschner N;
Int J Cancer; 2020 Mar; 146(5):1307-1315. PubMed ID: 31498894
[TBL] [Abstract][Full Text] [Related]
15. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM
Fishman M; Dutcher JP; Clark JI; Alva A; Miletello GP; Curti B; Agarwal N; Hauke R; Mahoney KM; Moon H; Treisman J; Tykodi SS; Daniels G; Morse MA; Wong MKK; Kaufman H; Gregory N; McDermott DF
J Immunother Cancer; 2019 Mar; 7(1):84. PubMed ID: 30917871
[TBL] [Abstract][Full Text] [Related]
16. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry.
Goebell PJ; Müller L; Hübner A; Harich HD; Boller E; Koska M; Jänicke M; Marschner N;
Urol Oncol; 2018 Oct; 36(10):470.e1-470.e9. PubMed ID: 30131294
[TBL] [Abstract][Full Text] [Related]
17. Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting.
Nikic P; Babovic N; Dzamic Z; Salma S; Stojanovic V; Matkovic S; Pejcic Z; Juskic K; Soldatovic I
Front Oncol; 2022; 12():892156. PubMed ID: 35756652
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Graham J; Wells JC; Donskov F; Lee JL; Fraccon A; Pasini F; Porta C; Bowman IA; Bjarnason GA; Ernst DS; Rha SY; Beuselinck B; Hansen A; North SA; Kollmannsberger CK; Wood LA; Vaishampayan UN; Pal SK; Choueiri TK; Heng DYC
Eur Urol Oncol; 2019 Nov; 2(6):643-648. PubMed ID: 31411994
[TBL] [Abstract][Full Text] [Related]
19. Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases.
Parmar A; Soliman H; Sahgal A; Bjarnason GA
Clin Genitourin Cancer; 2020 Jun; 18(3):e224-e232. PubMed ID: 32139300
[TBL] [Abstract][Full Text] [Related]
20. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.
Kroeger N; Choueiri TK; Lee JL; Bjarnason GA; Knox JJ; MacKenzie MJ; Wood L; Srinivas S; Vaishamayan UN; Rha SY; Pal SK; Yuasa T; Donskov F; Agarwal N; Tan MH; Bamias A; Kollmannsberger CK; North SA; Rini BI; Heng DY
Eur Urol; 2014 Jun; 65(6):1086-92. PubMed ID: 23916693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
